RecruitingNCT07312734

Study to Enable New Diagnostics for Pulmonary Microbes in People With CF

Study to Enable New Diagnostics for Pulmonary Microbes in People With CF (SEND-CF)

Sponsor

Chris Goss

Enrollment

300 participants

Start Date

Mar 30, 2026

Study Type

OBSERVATIONAL

Conditions

Cystic Fibrosis (CF)New Diagnostics

Summary

Sputum culture has been the best approach to detect harmful bacteria in the lungs of people with cystic fibrosis (CF). With the widespread use of new CF therapies (like Trikafta and Alyftrak), it is more difficult for people with CF to produce sputum even though they still have harmful bacteria in their lungs. The SEND-CF study is being done to see if there are other ways to detect harmful bacteria in the lungs.

Eligibility

Min Age: 16 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with cystic fibrosis (cf) and new diagnostics. The study is currently recruiting participants at 9 locations. People eligible for this study include aged 16 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.